GHK-Cu is not FDA-approved for any use. What you can buy, and from whom, depends entirely on the route [1]. A serum on a store shelf, a prescription cream and an injection each sit in a different place in FDA's rules. The GHK-Cu guide covers what the peptide is; this page covers where it stands.
GHK-Cu isn't an approved drug, so its status follows the route
Approval, cosmetic regulation and compounding policy answer different questions. A cosmetic label is not a drug approval; neither is a prescription or a substance’s presence in Category 1. Judge the intended use, exact formulation, source and applicable legal conditions separately.
| Version | FDA-approved? | Who makes it | Route under FDA rules | What it means for you |
|---|---|---|---|---|
| Cosmetic cream or serum | No; cosmetics are not approved | Skin-care brands | Generally no premarket approval; color-additive exception | Sold for appearance; treatment claims would make it a drug |
| Compounded topical (prescription) | No | A state-licensed 503A pharmacy | Category 1: FDA does not intend to act while it evaluates, if conditions are met | A prescription product FDA has not reviewed on its own |
| Compounded injection | No | No routine bulk-compounding basis established here | No category since April 22, 2026; outside the interim policy | No compounded injection is covered by FDA's policy |
| "Research use only" vial | No | Chemical suppliers | Research label alone does not authorize administration | Authorized clinical investigation is a separate framework, not permission supplied by a seller label |
Sources: FDA's 503A categories list (updated May 14, 2026); FDA safety-risks page (April 2026); FDA cosmetic or drug guidance page.
In skin care, GHK-Cu is a cosmetic ingredient that needs no approval
FDA's rule for cosmetics is short: "cosmetic products and ingredients, with the exception of color additives, do not require FDA approval before they go on the market" [4]. A copper-peptide serum sold to improve how skin looks is a cosmetic.
The line is the claim, not the ingredient. FDA says a product's intended use decides whether it is a cosmetic or a drug, and it gives examples of claims that make a product a drug, including claims to "regenerate cells" [4]. A GHK-Cu product sold to treat a skin condition or change how the body works is a drug, and an unapproved one.
Whether topical GHK-Cu does much for skin is a separate question. A small randomized trial in 13 patients after laser resurfacing found no difference in redness or wrinkles, though patients using it rated their skin better [5]. More on that in does topical GHK-Cu work.
As a compounded cream, GHK-Cu is in Category 1 for now
FDA describes three statutory bulk-ingredient bases for503A compounding: an applicable monograph, a component of an approved drug, or the bulks list. The separate interim Category 1 policy addresses nominated substances while evaluation continues [3]. It does not erase other compounding requirements.
FDA describes a conditional intention not to take specified enforcement action for Category 1 substances when its guidance conditions are met [3]. That enforcement position should not be presented as a finding that the substance is safe, effective or approved.
FDA's list, updated May 14, 2026, places "GHK-Cu (except for injectable routes of administration)" in Category 1 [1]. The document records the April withdrawal and May clarification directly.
The non-injectable Category 1 entry does not cover injections
FDA’s current list explains that GHK-Cu nominations were withdrawn in April 2026. A nominator then clarified that only injection was intended to be withdrawn; the non-injectable entry was restored in May [1]. This expressly excludes injection from that entry.
FDA's safety-risks page still carries the reasoning, in its table of substances whose nominations were withdrawn [2]:
FDA identifies possible immune reactions associated with peptide aggregation and impurities, and says human safety information is limited [2]. That is a stated potential risk; the source does not provide a reliable side-effect rate for a particular home product.
Leaving Category 2 is not a green light. Some reports describe injectable GHK-Cu as "banned"; it is more precise to say no compounding category covers it. The difference between the two routes is laid out in GHK-Cu topical vs injected.
What this means for you depends on the form
- Creams and serums from a store: cosmetics. Generally no premarket approval; no FDA finding that this product works.
- Prescription creams, foams or solutions: compounded drugs made under Category 1. FDA has not reviewed the product itself, so the pharmacy behind it matters.
- Injections: no established routine bulk-compounding pathway. A clinic offering GHK-Cu injections is not supplying a product covered by FDA's compounding policy.
- "Research use only" vials: not drugs for people, whatever the seller says about purity.
Ask for the product form and the pharmacy name
Two questions sort most offers. First, what form is it: cream, foam, serum or injection? Second, which pharmacy compounds it, and in which state is it licensed? A prescription topical should come with a pharmacy you can look up. An injection has no established routine bulk-compounding pathway to fill it.
A category listing does not verify a particular prescription
A pharmacy name, prescription or ingredient listing cannot establish the quality of a particular batch. Ask which pharmacy will actually dispense the product, the exact ingredient and strength, its intended use, and which testing and storage instructions apply. A named facility in a provider’s materials is not proof that it will fill your order. Our provider-check method explains those distinctions.
Investigational use has separate authorization and oversight requirements. Do not infer that all human research is forbidden simply because a substance lacks ordinary retail compounding eligibility. Conversely, a seller’s “research use only” label does not supply that authorization or make a retail vial suitable for treatment.
For the clinical question, use the claim-by-claim GHK-Cu evidence review. A regulatory category and an observed clinical benefit should never be treated as interchangeable.